gabapentin has been researched along with Endometrial Neoplasms in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled endometrial cancer patients undergoing open abdominal hysterectomy with lymphadenectomy by the same surgeon." | 1.40 | Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy. ( Jennings, PW; Santoso, JT; Ulm, MA; Wan, JY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potter, B | 1 |
| Schrager, S | 1 |
| Dalby, J | 1 |
| Torell, E | 1 |
| Hampton, A | 1 |
| Santoso, JT | 1 |
| Ulm, MA | 1 |
| Jennings, PW | 1 |
| Wan, JY | 1 |
| Fleming, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial[NCT02922985] | Phase 4 | 120 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 9 |
| Multimodal Pain Regimen Group | 9 |
Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 50.2 |
| Multimodal Pain Regimen Group | 50 |
neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 0 |
| Multimodal Pain Regimen Group | 4 |
Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 2 |
| Multimodal Pain Regimen Group | 6 |
Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery
| Intervention | Tablets (Median) |
|---|---|
| Placebo Control Group | 18 |
| Multimodal Pain Regimen Group | 19 |
Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 5 |
| Multimodal Pain Regimen Group | 6 |
Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 4 |
| Multimodal Pain Regimen Group | 3 |
Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 6 |
| Multimodal Pain Regimen Group | 6 |
Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 6.05 |
| Multimodal Pain Regimen Group | 6.35 |
Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | morphine milligram equivalents (Median) |
|---|---|
| Placebo Control Group | 42 |
| Multimodal Pain Regimen Group | 49.5 |
2 reviews available for gabapentin and Endometrial Neoplasms
| Article | Year |
|---|---|
Menopause.
Topics: Contraception; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Gabapentin; Hot Flashes; | 2018 |
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials | 2015 |
1 other study available for gabapentin and Endometrial Neoplasms
| Article | Year |
|---|---|
Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Bupivacaine; Cohort S | 2014 |